Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
Williams BJ, Bhatia S, Adams LK, Boling S, Carroll JL, Li XL, Rogers DL, Korokhov N, Kovesdi I, Pereboev AV, Curiel DT, Mathis JM.
Williams BJ, et al. Among authors: adams lk.
PLoS One. 2012;7(10):e46981. doi: 10.1371/journal.pone.0046981. Epub 2012 Oct 8.
PLoS One. 2012.
PMID: 23056548
Free PMC article.